Science Immunology

Supplementary Materials

Supplementary Material for:

Platelets subvert T cell immunity against cancer via GARP-TGFβ axis

Saleh Rachidi, Alessandra Metelli, Brian Riesenberg, Bill X. Wu, Michelle H. Nelson, Caroline Wallace, Chrystal M. Paulos, Mark P. Rubinstein, Elizabeth Garrett-Mayer, Mirko Hennig, Daniel W. Bearden, Yi Yang, Bei Liu, Zihai Li*

*Corresponding author. Email: zihai{at}

Published 5 May 2017, Sci. Immunol. 2, eaai7911 (2017)
DOI: 10.1126/sciimmunol.eaai7911

This PDF file includes:

  • Table S1. Source data for all the figure panels with small n (n < 20).
  • Fig. S1. Pf4-cre-Hsp90b1flox/flox (KO) mice show no noticeable immune dysfunction at baseline.
  • Fig. S2. PR, but not MVs, directly suppresses T cell proliferation and differentiation in vitro.
  • Fig. S3. Immune suppression by PR is independent of TCR signaling and specific to lymphocytes.
  • Fig. S4. T cell–suppressive function of the whole PR is significantly, but not completely, neutralized by blocking TGFβ pathway.
  • Fig. S5. A small–molecular weight, heat-stable, proteinase K–resistant T cell–suppressive fraction is shared between human and mouse PRs.
  • Fig. S6. TGFβ and LA in the PR are the major suppressors of CD8+ T cell activation.
  • Fig. S7. TGFβ contained in the PR drives Foxp3 expression and up-regulates p-Smad2/3.
  • Fig. S8. TGFβ1, but not LA, abrogates CD8-mediated tumor control.
  • Fig. S9. Platelet depletion has no effect on serum LA concentration.
  • Fig. S10. Inducible deletion of GARP from Foxp3+ Treg cells does not improve ACT of melanoma.
  • Fig. S11. Sample staining and isotype controls for flow cytometry.

Download PDF

Files in this Data Supplement: